ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

CD19+ Cell Behavior in the 12 Months Following a Single Dose of Rituximab in Patients with Humoral Rejection: Clinical and Histological Outcomes

L. Marino, I. A. Martínez-Juárez, J. R. Marino-Sánchez, J. I. Santander-Velez, F. Zamora, H. Juarez, R. Vazquez, L. Llorente, G. Lima, A. Cohen-Bucay, L. E. Morales-Buenrostro

Nephrology, INCMNSZ, Mexico City, Mexico

Meeting: 2019 American Transplant Congress

Abstract number: 115

Keywords: Kidney transplantation, Lymphocytes

Session Information

Session Name: Concurrent Session: Kidney Acute Antibody Mediated Rejection

Session Type: Concurrent Session

Date: Sunday, June 2, 2019

Session Time: 4:30pm-6:00pm

 Presentation Time: 5:30pm-5:42pm

Location: Ballroom B

*Purpose: Treatment of antibody mediated rejection (ABMR) commonly includes rituximab, but the dose needed is not yet well defined. It has been suggested that a single dose of rituximab is enough to deplete CD19+ cells. Aim: to analyze CD19+ cell behavior during the 12 months following a 500 mg dose of rituximab and its correlation with clinical and histological outcomes.

*Methods: This is a prospective cohort study of 122 kidney transplant recipients with biopsy proven ABMR who received a single dose of rituximab 500 mg as part of standard ABMR treatment between 2012 and 2018. Peripheral CD19+ cells were measured at baseline, 15, 30, 90, 180, 270, and 360 days after rituximab infusion, and correlated this data with clinical and histological outcomes.

*Results: 122 patients were included. Mean age was 27 y, 56.6% were female, in 93.4% of patients this was their first transplant, 71% were from living donors, and the median time to rejection was 6 y post-transplant. Treatment included plasmapheresis and IVIG in 75% of patients, 21% also received Bortezomib. All patients received 500 mg of rituximab, except for 7.3% of patients that received 375 mg/m2 BSA. Patients were followed for a median of 21 mo (0.1-83). Median allograft survival after ABMR was 5.5 years. CD19+ cell depletion patterns are shown in Figure 1. CD19+ cell depletion (<10 cells) at 1 month was associated with less IFTA at follow-up biopsy and improvement of proteinuria at last follow-up. Early CD19+ cell repopulation was associated with higher graft loss and dead. Persistent CD19+ cell depletion (<10 cells) at 12mo was associated with better graft and patient survival.

*Conclusions: A single dose of Rituximab achieved CD19+ cell depletion in more than 80% of patients, which lasted at least 6 months. CD19+ cell depletion is associated with improvement of proteinuria and less IFTA; and the persistence of CD19+ cell depletion at 12 months improves graft and patient survival.

 border=

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

To cite this abstract in AMA style:

Marino L, Martínez-Juárez IA, Marino-Sánchez JR, Santander-Velez JI, Zamora F, Juarez H, Vazquez R, Llorente L, Lima G, Cohen-Bucay A, Morales-Buenrostro LE. CD19+ Cell Behavior in the 12 Months Following a Single Dose of Rituximab in Patients with Humoral Rejection: Clinical and Histological Outcomes [abstract]. Am J Transplant. 2019; 19 (suppl 3). https://atcmeetingabstracts.com/abstract/cd19-cell-behavior-in-the-12-months-following-a-single-dose-of-rituximab-in-patients-with-humoral-rejection-clinical-and-histological-outcomes/. Accessed June 2, 2025.

« Back to 2019 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences